Sandy Spring Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sandy Spring Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$24.8K	Sell	92 -5	-5%	-$1.28K	﹤0.01%	695
2024 Q4	$22.8K	Sell	97 -9	-8%	-$2.37K	﹤0.01%	724
2024 Q3	$29.2K	Hold	106	–	–	﹤0.01%	697
2024 Q2	$25.8K	Hold	106	–	–	﹤0.01%	705
2024 Q1	$15.8K	Buy	106 +31	+41%	+$5.17K	﹤0.01%	779
2023 Q4	$14.4K	Hold	75	–	–	﹤0.01%	765
2023 Q3	$13.3K	Hold	75	–	–	﹤0.01%	771
2023 Q2	$14.2K	Hold	75	–	–	﹤0.01%	773
2023 Q1	$15K	Hold	75	–	–	﹤0.01%	752
2022 Q4	$17.8K	Buy	+75	New	+$16K	﹤0.01%	720
2020 Q3	–	Sell	-25	Closed	-$4K	–	926
2020 Q2	$4K	Buy	+25	New	+$3.37K	﹤0.01%	776

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sandy Spring Bank's ALNY Position: Q1 2025 in Review

Sandy Spring Bank reduced its Alnylam Pharmaceuticals (ALNY) stake by 5.2% in Q1 2025, selling an estimated $1.28K and leaving 92 shares worth $24.8K. The position accounts for ﹤0.01% of the portfolio, ranked #695.

Sandy Spring Bank first reported a position in ALNY in Q2 2020 and has held it in 11 quarters since. The position peaked at $29.2K in Q3 2024. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

Sandy Spring Bank held 92 shares of Alnylam Pharmaceuticals worth $24.8K as of Q1 2025.
Sandy Spring Bank sold 5 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $1.28K.
Alnylam Pharmaceuticals made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #695 holding.
Sandy Spring Bank first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
Sandy Spring Bank's Alnylam Pharmaceuticals position peaked at $29.2K in Q3 2024.
627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.